ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet9765ometendo-9765Research ArticleОбзор литературыReviewВоспаление жировой ткани. Есть ли место статинам для коррекции адипозопатии?Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?https://orcid.org/0000-0002-6221-3509БородкинаДарья АндреевнаBorodkinaDaria A.

к.м.н.

MD, PhD

alpheia@mail.ruhttps://orcid.org/0000-0002-7780-829XГруздеваОльга ВикторовнаGruzdevaOlga V.

д.м.н., заведующая лабораторией  исследования  гомеостаза отдела  диагностики сердечно-сосудистых заболеваний

MD, ScD, head of the Homeostasis Research Laboratory of the Cardiovascular Disease Diagnostics Department

o_gruzdeva@mail.ruhttps://orcid.org/0000-0002-5642-7746ПаличеваЕлена ИвановнаPalichevaElena V.

к.м.н., доцент старший научный сотрудник лаборатории исследований гомеостаза отдела диагностики сердечно-сосудистых заболеваний

MD, PhD, Associate professor 

palichevaelena@rambler.ruhttps://orcid.org/0000-0002-4642-3610БарбарашОльга ЛеонидовнаBarbarashOlga L.

д.м.н., профессор, чл.-корр. РАН Член-Корреспондент РАН, д.м.н. профессор, директор ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний.

MD, ScD, professor, corresponding member of the Russian Academy of Sciences, Director of Institute for Complex Issues of Cardiovascular Diseases

olb61@mail.ru<p>ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ГАУЗ КО &laquo;Кемеровская областная клиническая больница&raquo; имени С.В. Беляева, областной диабетологический центр</p>Россия<p>Institute for Complex Issues of Cardiovascular Diseases; Kemerovo regional clinical hospital, Regional diabetes center</p>Russian Federation<p>ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ФГБОУ ВО &laquo;Кемеровский государственный медицинский университет&raquo; Минздрава России</p>Россия<p>Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University</p> <p>&nbsp;</p>Russian Federation<p>ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ФГБОУ ВО &laquo;Кемеровский государственный медицинский университет&raquo; Минздрава России</p>Россия<p>Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University</p>Russian Federation2019200620191611219Copyright &#x00A9; Бородкина Д.А., Груздева О.В., Паличева Е.И., Барбараш О.Л., 20192019Бородкина Д.А., Груздева О.В., Паличева Е.И., Барбараш О.Л.Borodkina D.A., Gruzdeva O.V., Palicheva E.V., Barbarash O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/9765

Настоящий обзор посвящен анализу данных по изучению влияния ингибиторов 3-гидрокси-3-метилглутарил-кофермента А-редуктазы на эндокринную функцию жировой ткани на фоне ожирения. Нарушение метаболизма жировой ткани, как и количество жира, является ключевым фактором в патофизиологии ожирения и развитии сопутствующих ему заболеваний. Статины являются конкурентными ингибиторами 3-гидрокси-3-метилглутарил-кофермента А-редуктазы (ГМГ-КоА-редуктазы), катализирующей начальные стадии биосинтеза холестерола в печени. Поэтому традиционно печень рассматривается как основной орган-мишень для статинов. В работе отражены результаты исследований молекулярных механизмов действия статинов на углеводный и липидный обмен, адипокиновый и воспалительный баланс в жировой ткани на примере изолированных адипоцитов (in vivo) и в живом организме (in vitro), влияние статинов на действие инсулина, а также возможности развития патологических состояний, связанных с инсулинорезистентностью и развитием сахарного диабета 2 типа (СД2). Доказанные клинические эффекты гипохолестеринемического действия статинов позволяют по-новому взглянуть и еще глубже изучать их возможное влияние и на другие звенья в развитии ожирения, а в перспективе – использовать их в качестве терапевтического средства для медикаментозной коррекции ожирения и борьбы с сердечно-сосудистыми заболеваниями.

This review is devoted to the analysis of data on the effect of inhibitors of 3-hydroxy-3-methylglutaryl coenzymate-reductase on the endocrine function of adipose tissue in obesity. Violation of metabolism of adipose tissue, as well as the amount of fat, are a a key factor in the pathophysiology of obesity and the development of concomitant diseases. Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-kofermenta reductase (HMG-COA reductase) that catalyze the initial stage of cholesterol biosynthesis in the liver. Therefore, traditionally, the liver is considered as the main target organ for statins. The results of studies of molecular mechanisms of action of statins on carbohydrate and lipid metabolism, adipokine and inflammatory balance in adipose tissue on the example of isolated adipocytes (in vivo) and in living organism (in vitro) are presented. Effect of statins on the action of insulin, as well as the possibility of developing pathological conditions associated with insulin resistance and the development of type 2 diabetes mellitus (DM 2). The proven clinical effects of cholesterol-lowering action of statins, allow new insights and to further explore their possible impact on other links in the development of obesity, and potentially to use them as therapeutic agents for pharmacological correction of obesity and the fight against cardiovascular diseases.

статиныадипозопатияжировая тканьstatinsadiposopathyadipose tissueReferencesКрысанова В.С., Журавлева М.В., Сереброва С.Ю. Социальная и экономическая значимость избыточной массы тела и ожирения в Российской Федерации. Основные подходы к лечению ожирения // Русский медицинский журнал. — 2015. — Т.23. — №26. — С.1534-1537. [Krysanova VS., Zhuravleva MV., Serebrova SYu. Sotsial'naya i ekonomicheskaya znachimost' izbytochnoi massy tela i ozhireniya v Rossiiskoi Federatsii. Osnovnye podkhody k lecheniyu ozhireniya. RMŽ. 2015;23(26):1534-1537. (In Russ.)]Крысанова В.С., Журавлева М.В., Сереброва С.Ю. Социальная и экономическая значимость избыточной массы тела и ожирения в Российской Федерации. Основные подходы к лечению ожирения // Русский медицинский журнал. — 2015. — Т.23. — №26. — С.1534-1537. [Krysanova VS., Zhuravleva MV., Serebrova SYu. Sotsial'naya i ekonomicheskaya znachimost' izbytochnoi massy tela i ozhireniya v Rossiiskoi Federatsii. Osnovnye podkhody k lecheniyu ozhireniya. RMŽ. 2015;23(26):1534-1537. (In Russ.)]Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977. doi: 10.1161/01.CIR.67.5.968Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977. doi: 10.1161/01.CIR.67.5.968World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation, World Health Organization Technical Report Series, 1998 Report No.: 894World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation, World Health Organization Technical Report Series, 1998 Report No.: 894Tchernof A, Després J-P. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. doi: 10.1152/physrev.00033.2011Tchernof A, Després J-P. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. doi: 10.1152/physrev.00033.2011Bergman RN, Kim SP, Catalano KJ, et al. Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome. Obesity. 2006;14(2S):16S-19S. doi: 10.1038/oby.2006.277Bergman RN, Kim SP, Catalano KJ, et al. Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome. Obesity. 2006;14(2S):16S-19S. doi: 10.1038/oby.2006.277Bays HE. Adiposopathy. J Am Coll Cardiol. 2011;57(25):2461-2473. doi: 10.1016/j.jacc.2011.02.038Bays HE. Adiposopathy. J Am Coll Cardiol. 2011;57(25):2461-2473. doi: 10.1016/j.jacc.2011.02.038Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2013;129(25 suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7aStone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2013;129(25 suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7aFerroni P, Basili S, Davi G. Platelet Activation, Inflammatory Mediators and Hypercholesterolemia. Curr Vasc Pharmacol. 2003;1(2):157-169. doi: 10.2174/1570161033476772Ferroni P, Basili S, Davi G. Platelet Activation, Inflammatory Mediators and Hypercholesterolemia. Curr Vasc Pharmacol. 2003;1(2):157-169. doi: 10.2174/1570161033476772Бородкина Д.А., Груздева О.В., Квиткова Л.В., Барбараш О.Л. Можно ли назвать висцеральное ожирение ключевым фактором парадокса ожирения? // Проблемы Эндокринологии. – 2016. – Т.62. – №6. – C.33-39. [Borodkina DA, Gruzdeva OV, Kvitkova LV, Barbarash OL. Is visceral obesity the cause of obesity paradox? Problems of endocrinology. 2016;62(6):33-39. (In Russ.)] doi: 10.14341/probl201662633-39Бородкина Д.А., Груздева О.В., Квиткова Л.В., Барбараш О.Л. Можно ли назвать висцеральное ожирение ключевым фактором парадокса ожирения? // Проблемы Эндокринологии. – 2016. – Т.62. – №6. – C.33-39. [Borodkina DA, Gruzdeva OV, Kvitkova LV, Barbarash OL. Is visceral obesity the cause of obesity paradox? Problems of endocrinology. 2016;62(6):33-39. (In Russ.)] doi: 10.14341/probl201662633-39Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2016;54:68-81. doi: 10.1016/j.semcdb.2015.10.039Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2016;54:68-81. doi: 10.1016/j.semcdb.2015.10.039SENGENÈS C, BERLAN M, DE GLISEZINSKI I, LAFONTAN M, GALITZKY J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14(10):1345-1351. doi: 10.1096/fasebj.14.10.1345SENGENÈS C, BERLAN M, DE GLISEZINSKI I, LAFONTAN M, GALITZKY J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14(10):1345-1351. doi: 10.1096/fasebj.14.10.1345Gomes A, Correia G, Coelho M, et al. Dietary unsaturated fatty acids differently affect catecholamine handling by adrenal chromaffin cells. J Nutr Biochem. 2015;26(5):563-570. doi: 10.1016/j.jnutbio.2014.12.009Gomes A, Correia G, Coelho M, et al. Dietary unsaturated fatty acids differently affect catecholamine handling by adrenal chromaffin cells. J Nutr Biochem. 2015;26(5):563-570. doi: 10.1016/j.jnutbio.2014.12.009Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908. doi: 10.1016/j.pharmthera.2006.02.003Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908. doi: 10.1016/j.pharmthera.2006.02.003Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr. 1998;80(06):495-502. doi: 10.1017/S0007114598001585Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr. 1998;80(06):495-502. doi: 10.1017/S0007114598001585Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. N Engl J Med. 2001;344(26):1959-1965. doi: 10.1056/NEJM200106283442601Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. N Engl J Med. 2001;344(26):1959-1965. doi: 10.1056/NEJM200106283442601Sacks FM, Pfeffer M a, Moye L a, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. N Engl J Med. 1996;335(14):1001-1009. doi: 10.1056/NEJM199610033351401Sacks FM, Pfeffer M a, Moye L a, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. N Engl J Med. 1996;335(14):1001-1009. doi: 10.1056/NEJM199610033351401Vega G-L, Grundy SM. Effect of Statins on Metabolism of Apo-B–Containing Lipoproteins in Hypertriglyceridemic Men. Am J Cardiol. 1998;81(4):36B-42B. doi: 10.1016/S0002-9149(98)00036-8Vega G-L, Grundy SM. Effect of Statins on Metabolism of Apo-B–Containing Lipoproteins in Hypertriglyceridemic Men. Am J Cardiol. 1998;81(4):36B-42B. doi: 10.1016/S0002-9149(98)00036-8Rodríguez-Calvo R, Barroso E, Serrano L, et al. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology. 2009;49(1):106-115. doi: 10.1002/hep.22570Rodríguez-Calvo R, Barroso E, Serrano L, et al. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology. 2009;49(1):106-115. doi: 10.1002/hep.22570Miller G., Miller N. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE. Lancet. 1975;305(7897):16-19. doi: 10.1016/S0140-6736(75)92376-4Miller G., Miller N. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE. Lancet. 1975;305(7897):16-19. doi: 10.1016/S0140-6736(75)92376-4Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 1996;7(4):209-216. doi: 10.1097/00041433-199608000-00007Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 1996;7(4):209-216. doi: 10.1097/00041433-199608000-00007Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci. 1991;88(2):434-438. doi: 10.1073/pnas.88.2.434Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci. 1991;88(2):434-438. doi: 10.1073/pnas.88.2.434Bencharif K, Hoareau L, Murumalla RK, et al. Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids Health Dis. 2010;9(1):75. doi: 10.1186/1476-511X-9-75Bencharif K, Hoareau L, Murumalla RK, et al. Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids Health Dis. 2010;9(1):75. doi: 10.1186/1476-511X-9-75Krautbauer S, Neumeier M, Eisinger K, et al. LDL but not HDL increases adiponectin release of primary human adipocytes. Exp Mol Pathol. 2013;95(3):325-329. doi: 10.1016/j.yexmp.2013.10.002Krautbauer S, Neumeier M, Eisinger K, et al. LDL but not HDL increases adiponectin release of primary human adipocytes. Exp Mol Pathol. 2013;95(3):325-329. doi: 10.1016/j.yexmp.2013.10.002Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212(1):131-138. doi: 10.1016/j.atherosclerosis.2010.04.019Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212(1):131-138. doi: 10.1016/j.atherosclerosis.2010.04.019Alexopoulos N, Melek BH, Arepalli CD, et al. Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women. J Am Coll Cardiol. 2013;61(19):1956-1961. doi: 10.1016/j.jacc.2012.12.051Alexopoulos N, Melek BH, Arepalli CD, et al. Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women. J Am Coll Cardiol. 2013;61(19):1956-1961. doi: 10.1016/j.jacc.2012.12.051Krysiak R, Żmuda W, Okopień B. The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report. Pharmacol Reports. 2014;66(5):880-884. doi: 10.1016/j.pharep.2014.05.012Krysiak R, Żmuda W, Okopień B. The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report. Pharmacol Reports. 2014;66(5):880-884. doi: 10.1016/j.pharep.2014.05.012Zhao S, Wu Z. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta. 2005;360(1-2):133-140. doi: 10.1016/j.cccn.2005.04.021Zhao S, Wu Z. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta. 2005;360(1-2):133-140. doi: 10.1016/j.cccn.2005.04.021Krysiak R, Zmuda W, Okopien B. The Effect of Simvastatin-Ezetimibe Combination Therapy on Adipose Tissue Hormones and Systemic Inflammation in Patients with Isolated Hypercholesterolemia. Cardiovasc Ther. 2014;32(2):40-46. doi: 10.1111/1755-5922.12057Krysiak R, Zmuda W, Okopien B. The Effect of Simvastatin-Ezetimibe Combination Therapy on Adipose Tissue Hormones and Systemic Inflammation in Patients with Isolated Hypercholesterolemia. Cardiovasc Ther. 2014;32(2):40-46. doi: 10.1111/1755-5922.12057Kaplan NM. The CARE study: a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther. 1996;18(4):658-670. doi: 10.1016/S0149-2918(96)80216-5Kaplan NM. The CARE study: a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther. 1996;18(4):658-670. doi: 10.1016/S0149-2918(96)80216-5The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med. 1998;339(19):1349-1357. doi: 10.1056/NEJM199811053391902The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med. 1998;339(19):1349-1357. doi: 10.1056/NEJM199811053391902Wallace AM, McMahon AD, Packard CJ, et al. Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104(25):3052-3056. doi: 10.1161/hc5001.101061Wallace AM, McMahon AD, Packard CJ, et al. Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104(25):3052-3056. doi: 10.1161/hc5001.101061Downs JR, Clearfield M, Weis S, et al. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels. JAMA. 1998;279(20):1615-1622. doi: 10.1001/jama.279.20.1615Downs JR, Clearfield M, Weis S, et al. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels. JAMA. 1998;279(20):1615-1622. doi: 10.1001/jama.279.20.1615PEDERSEN TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004;5(3):81-87. doi: 10.1016/j.atherosclerosissup.2004.08.027PEDERSEN TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004;5(3):81-87. doi: 10.1016/j.atherosclerosissup.2004.08.027Wang K, Bao L, Zhou N, et al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. J Med Chem. 2018;61(8):3609-3625. doi: 10.1021/acs.jmedchem.8b00107Wang K, Bao L, Zhou N, et al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. J Med Chem. 2018;61(8):3609-3625. doi: 10.1021/acs.jmedchem.8b00107Yamada Y, Takeuchi S, Yoneda M, et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol. 2017;240:332-338. doi: 10.1016/j.ijcard.2017.04.103Yamada Y, Takeuchi S, Yoneda M, et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol. 2017;240:332-338. doi: 10.1016/j.ijcard.2017.04.103Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic Action of AMP-activated Protein Kinase in Rodent Adipocytes. J Biol Chem. 2005;280(26):25250-25257. doi: 10.1074/jbc.M414222200Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic Action of AMP-activated Protein Kinase in Rodent Adipocytes. J Biol Chem. 2005;280(26):25250-25257. doi: 10.1074/jbc.M414222200Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000;152(2):359-366. doi: 10.1016/S0021-9150(00)00454-8Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000;152(2):359-366. doi: 10.1016/S0021-9150(00)00454-8Laumen H, Skurk T, Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008;196(2):565-573. doi: 10.1016/j.atherosclerosis.2007.06.005Laumen H, Skurk T, Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008;196(2):565-573. doi: 10.1016/j.atherosclerosis.2007.06.005Wang C-Y, Liu P-Y, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44. doi: 10.1016/j.molmed.2007.11.004Wang C-Y, Liu P-Y, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44. doi: 10.1016/j.molmed.2007.11.004Payne G, Tune J, Knudson J. Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions. Curr Pharm Des. 2014;20(4):603-608. doi: 10.2174/13816128113199990017Payne G, Tune J, Knudson J. Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions. Curr Pharm Des. 2014;20(4):603-608. doi: 10.2174/13816128113199990017Sun Y-M, Li J, Luan Y, Wang L-F. Effect of statin therapy on leptin levels in patients with coronary heart disease. Peptides. 2010;31(6):1205-1207. doi: 10.1016/j.peptides.2010.03.023Sun Y-M, Li J, Luan Y, Wang L-F. Effect of statin therapy on leptin levels in patients with coronary heart disease. Peptides. 2010;31(6):1205-1207. doi: 10.1016/j.peptides.2010.03.023Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197-203. doi: 10.1016/j.atherosclerosis.2012.04.015Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197-203. doi: 10.1016/j.atherosclerosis.2012.04.015Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. J Endocrinol Invest. 2008;31(1):42-47. doi: 10.1007/BF03345565Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. J Endocrinol Invest. 2008;31(1):42-47. doi: 10.1007/BF03345565Szotowska M, Czerwienska B, Adamczak M, et al. Effect of Low-Dose Atorvastatin on Plasma Concentrations of Adipokines in Patients with Metabolic Syndrome. Kidney Blood Press Res. 2012;35(4):226-232. doi: 10.1159/000332403Szotowska M, Czerwienska B, Adamczak M, et al. Effect of Low-Dose Atorvastatin on Plasma Concentrations of Adipokines in Patients with Metabolic Syndrome. Kidney Blood Press Res. 2012;35(4):226-232. doi: 10.1159/000332403Singh P, Zhang Y, Sharma P, et al. Statins decrease leptin expression in human white adipocytes. Physiol Rep. 2018;6(2):e13566. doi: 10.14814/phy2.13566Singh P, Zhang Y, Sharma P, et al. Statins decrease leptin expression in human white adipocytes. Physiol Rep. 2018;6(2):e13566. doi: 10.14814/phy2.13566Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(4):304-383. doi: 10.1016/j.jacl.2013.04.001Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(4):304-383. doi: 10.1016/j.jacl.2013.04.001Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208. doi: 10.1016/j.atherosclerosis.2016.07.897Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208. doi: 10.1016/j.atherosclerosis.2016.07.897Elfakhani M, Torabi S, Hussein D, et al. Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes. Exp Biol Med. 2014;239(3):293-301. doi: 10.1177/1535370213517614Elfakhani M, Torabi S, Hussein D, et al. Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes. Exp Biol Med. 2014;239(3):293-301. doi: 10.1177/1535370213517614Papathanassiou M, Nikita E, Theodossiadis P, Vergados I. Orbital metastasis secondary to breast cancer mimicking thyroid-associated ophthalmopathy. Clin Exp Optom. 2010;93(5):368-369. doi: 10.1111/j.1444-0938.2010.00494.xPapathanassiou M, Nikita E, Theodossiadis P, Vergados I. Orbital metastasis secondary to breast cancer mimicking thyroid-associated ophthalmopathy. Clin Exp Optom. 2010;93(5):368-369. doi: 10.1111/j.1444-0938.2010.00494.xTomiyama K, Nishio E, Watanabe Y. Both Wortmannin and Simvastatin Inhibit the Adipogenesis in 3T3-L1 Cells During the Late Phase of Differentiation. Jpn J Pharmacol. 1999;80(4):375-378. doi: 10.1254/jjp.80.375Tomiyama K, Nishio E, Watanabe Y. Both Wortmannin and Simvastatin Inhibit the Adipogenesis in 3T3-L1 Cells During the Late Phase of Differentiation. Jpn J Pharmacol. 1999;80(4):375-378. doi: 10.1254/jjp.80.375Khan T, Hamilton MP, Mundy DI, et al. Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo. Endocrinology. 2009;150(12):5262-5272. doi: 10.1210/en.2009-0603Khan T, Hamilton MP, Mundy DI, et al. Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo. Endocrinology. 2009;150(12):5262-5272. doi: 10.1210/en.2009-0603Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822. doi: 10.2337/dc08-9018Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822. doi: 10.2337/dc08-9018Roehrich M-E, Mooser V, Lenain V, et al. Insulin-secreting β-Cell Dysfunction Induced by Human Lipoproteins. J Biol Chem. 2003;278(20):18368-18375. doi: 10.1074/jbc.M300102200Roehrich M-E, Mooser V, Lenain V, et al. Insulin-secreting β-Cell Dysfunction Induced by Human Lipoproteins. J Biol Chem. 2003;278(20):18368-18375. doi: 10.1074/jbc.M300102200Sattar N, Taskinen M-R. Statins are diabetogenic – Myth or reality? Atheroscler Suppl. 2012;13(1):1-10. doi: 10.1016/j.atherosclerosissup.2012.06.001Sattar N, Taskinen M-R. Statins are diabetogenic – Myth or reality? Atheroscler Suppl. 2012;13(1):1-10. doi: 10.1016/j.atherosclerosissup.2012.06.001Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881-1892. doi: 10.1007/s00125-006-0269-5Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881-1892. doi: 10.1007/s00125-006-0269-5Graham I, Atar D, Borch-Johnsen K, et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(2_suppl):E1-E40. doi: 10.1097/01.hjr.0000277984.31558.c4Graham I, Atar D, Borch-Johnsen K, et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(2_suppl):E1-E40. doi: 10.1097/01.hjr.0000277984.31558.c4Kanda M, Satoh K, Ichihara K. Effects of Atorvastatin and Pravastatin on Glucose Tolerance in Diabetic Rats Mildly Induced by Streptozotocin. Biol Pharm Bull. 2003;26(12):1681-1684. doi: 10.1248/bpb.26.1681Kanda M, Satoh K, Ichihara K. Effects of Atorvastatin and Pravastatin on Glucose Tolerance in Diabetic Rats Mildly Induced by Streptozotocin. Biol Pharm Bull. 2003;26(12):1681-1684. doi: 10.1248/bpb.26.1681Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of Atorvastatin and Pravastatin on Signal Transduction Related to Glucose Uptake in 3T3L1 Adipocytes. J Pharmacol Sci. 2008;107(1):80-89. doi: 10.1254/jphs.FP0072403Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of Atorvastatin and Pravastatin on Signal Transduction Related to Glucose Uptake in 3T3L1 Adipocytes. J Pharmacol Sci. 2008;107(1):80-89. doi: 10.1254/jphs.FP0072403Ishikawa M, Namiki A, Kubota T, et al. Effect of Pravastatin and Atorvastatin on Glucose Metabolism in NonDiabetic Patients with Hypercholesterolemia. Intern Med. 2006;45(2):51-55. doi: 10.2169/internalmedicine.45.1476Ishikawa M, Namiki A, Kubota T, et al. Effect of Pravastatin and Atorvastatin on Glucose Metabolism in NonDiabetic Patients with Hypercholesterolemia. Intern Med. 2006;45(2):51-55. doi: 10.2169/internalmedicine.45.1476

The authors declare that there are no conflicts of interest present.